The evaluation of the cytotoxicity of Epo and LFM-A13 used together in both DLD-1 and HT-29 colon cancer cells demonstrated that this combination had a greater antiproliferative effect than the use of the latter drug alone. This evidence concerns the gene EPO and malignant colon neoplasm.